Table 1.

Patient Demographics and Clinical Information

COVID-19 patients (n = 7)∗	Age	Sex	Cardiac history	Medications	Cause of death
Patient 1	94	F	CAD	Remdesivir	Pneumonia
Patient 2	65	F	CAD, DVT, NSTEMI	Prednisone, Rivaroxaban	Pneumonia w/DAD leading to ARDS
Patient 3	77	M	None		Pneumonia and pulmonary thrombosis in setting of end stage renal disease
Patient 4	57	M	None		Pneumonia leading to cardiac arrest, followed by shock
Patient 5	90	M	CAD, stroke		Pneumonia w/DAD
Patient 6	68	F	CAD, MI		Pneumonia in setting of CV disease and recent MI
Patient 7	50	M	None	Bilnatumomab	Pneumonia w/DAD in setting of B cell ALL relapse
Controls (n = 12)
Control 1	89	M	CAD, stroke		Atherosclerotic and hypertensive CV disease
Control 2	47	M	CAD, MI		CHF
Control 3	79	M	Atrial Flutter, CKD		CHF
Control 4	58	F	None		Respiratory failure from pulmonary adenocarcinoma
Control 5	58	M	None		GI hemorrhage and shock from cirrhosis
Control 6	46	F	HOCM		Metastatic breast cancer in setting of HOCM-induced heart failure
Control 7	68	M	None		Pulmonary squamous cell carcinoma leading to hemorrhage and desanguination
Control 8	65	M	CAD		Interstitial lung disease complicated by bronchopneumonia
Control 9	71	F	None		ILD leading to pneumonia
Control 10	62	F	None		Metastatic breast cancer
Control 11	68	M	CAD		Cirrhosis leading to esophageal varices and bleeding
Control 12	53	M	CAD		GI bleeding from cirrhosis

F, female; M, male; ALL, acute lymphoblastic leukemia; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; DAD, diffuse alveolar damage; DVT, deep venous thrombosis; GI, gastrointestinal; HOCM, hypertrophic obstructive cardiomyopathy; ILD, interstitial lung disease; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction.

^∗All patients with COVID-19 were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by RT-PCR.